Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Non-Current Debt (2021 - 2025)

Historic Non-Current Debt for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $304.0 million.

  • Indivior Pharmaceuticals' Non-Current Debt changed N/A to $304.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $304.0 million, marking a year-over-year change of. This contributed to the annual value of $315.0 million for FY2024, which is 3291.14% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Non-Current Debt of $304.0 million as of Q3 2025.
  • Indivior Pharmaceuticals' Non-Current Debt's 5-year high stood at $315.0 million during Q4 2024, with a 5-year trough of $237.0 million in Q4 2022.
  • In the last 5 years, Indivior Pharmaceuticals' Non-Current Debt had a median value of $304.0 million in 2025 and averaged $278.7 million.
  • In the last 5 years, Indivior Pharmaceuticals' Non-Current Debt plummeted by 83.68% in 2022 and then soared by 3291.14% in 2024.
  • Indivior Pharmaceuticals' Non-Current Debt (Quarter) stood at $239.0 million in 2021, then fell by 0.84% to $237.0 million in 2022, then changed by 0.0% to $237.0 million in 2023, then soared by 32.91% to $315.0 million in 2024, then fell by 3.49% to $304.0 million in 2025.
  • Its last three reported values are $304.0 million in Q3 2025, $308.0 million for Q2 2025, and $311.0 million during Q1 2025.